SETTING: Two tuberculosis (TB) reference hospitals in Maputo, Mozambique. OBJECTIVES: To assess the pattern of TB drug resistance and its risk factors in human immunodeficiency virus (HIV) patients. DESIGN: Adult HIV-positive patients with TB diagnosed by culture of sputum or bronchial washing were enrolled during 2002-2003. Cultures of 111 patients were tested for rifampicin, isoniazid, streptomycin and ethambutol sensitivity. Chest X-ray, haemoglobin (Hb), total lymphocyte and CD4 counts were also performed. RESULTS: Overall resistance to any drugs was found in 18% and multidrug-resistant TB (MDR-TB) in 9%. New cases of TB accounted for 62% of the studied group. Drug resistance in this subgroup was 13% compared with 26.3% in the previously treated subgroup, and MDR-TB was 5.8% vs. 15.8%. All patients presented Hb levels < 9 g/dl and total lymphocyte counts < 1200/microl. CD4 counts were significantly low in the drug resistance subgroup, with levels mostly < 100/microl. Cavities on X-ray were seen only in drug-sensitive patients. No risk factors for drug resistance were detected. CONCLUSIONS: Overall observed drug resistance was 18%, and MDR-TB 9%. Previously treated patients had high drug resistance (26.3%) and MDR-TB (15.8%).
SETTING: Two tuberculosis (TB) reference hospitals in Maputo, Mozambique. OBJECTIVES: To assess the pattern of TB drug resistance and its risk factors in human immunodeficiency virus (HIV) patients. DESIGN: Adult HIV-positive patients with TB diagnosed by culture of sputum or bronchial washing were enrolled during 2002-2003. Cultures of 111 patients were tested for rifampicin, isoniazid, streptomycin and ethambutol sensitivity. Chest X-ray, haemoglobin (Hb), total lymphocyte and CD4 counts were also performed. RESULTS: Overall resistance to any drugs was found in 18% and multidrug-resistant TB (MDR-TB) in 9%. New cases of TB accounted for 62% of the studied group. Drug resistance in this subgroup was 13% compared with 26.3% in the previously treated subgroup, and MDR-TB was 5.8% vs. 15.8%. All patients presented Hb levels < 9 g/dl and total lymphocyte counts < 1200/microl. CD4 counts were significantly low in the drug resistance subgroup, with levels mostly < 100/microl. Cavities on X-ray were seen only in drug-sensitive patients. No risk factors for drug resistance were detected. CONCLUSIONS: Overall observed drug resistance was 18%, and MDR-TB 9%. Previously treated patients had high drug resistance (26.3%) and MDR-TB (15.8%).
Authors: Simone C M Ribeiro; Lia Lima Gomes; Eduardo P Amaral; Marcelle R M Andrade; Fabricio M Almeida; Andreza L Rezende; Verônica R Lanes; Eulógio C Q Carvalho; Philip N Suffys; Igor Mokrousov; Elena B Lasunskaia Journal: J Clin Microbiol Date: 2014-05-14 Impact factor: 5.948
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: Philip Erik Wikman-Jorgensen; Alejandra Morales-Cartagena; Jara Llenas-García; Tomàs Maria Pérez-Porcuna; Michael Hobbins; Jochen Ehmer; Manuel Aly Mussa; Rosa Abellana; Carlos Ascaso Journal: Pathog Glob Health Date: 2015-08-04 Impact factor: 2.894
Authors: Yì Xiáng J Wáng; Myung Jin Chung; Aliaksandr Skrahin; Alex Rosenthal; Andrei Gabrielian; Michael Tartakovsky Journal: Quant Imaging Med Surg Date: 2018-03
Authors: James C M Brust; Melissa Lygizos; Krisda Chaiyachati; Michelle Scott; Theo L van der Merwe; Anthony P Moll; Xuan Li; Marian Loveday; Sheila A Bamber; Umesh G Lalloo; Gerald H Friedland; N Sarita Shah; Neel R Gandhi Journal: PLoS One Date: 2011-01-06 Impact factor: 3.240
Authors: Jaya Faujdar; Pushpa Gupta; Mohan Natrajan; Ram Das; D S Chauhan; V M Katoch; U D Gupta Journal: Indian J Med Res Date: 2011-11 Impact factor: 2.375